Excitement Builds for Tremfya Among US Gastroenterologists as the FDA Approves its Expansion into Crohn’s Disease, Suggesting the Brand May Impact Competitor Skyrizi’s Growth (GlobeNewswire)

Johnson & Johnson’s Tremfya (guselkumab) has been FDA-approved for Crohn’s disease, joining IL-23 class peers Skyrizi and Omvoh. Backed by strong brand familiarity and high prescriber interest, 25% of gastroenterologists plan to shift prescribing from Skyrizi to Tremfya. Its subcutaneous induction dosing—a unique feature—makes it more convenient than IV therapies, which is driving enthusiasm. Tremfya has also gained momentum in ulcerative colitis, aided by AGA guideline endorsements and strong trial data.